The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sica, A.
Right arrow Articles by Mantovani, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sica, A.
Right arrow Articles by Mantovani, A.
The Journal of Immunology, 2000, 164: 762-767.
Copyright © 2000 by The American Association of Immunologists

Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF-{kappa}B Activation in Tumor-Associated Macrophages1

Antonio Sica2,*, Alessandra Saccani*, Barbara Bottazzi*, Nadia Polentarutti*, Annunciata Vecchi*, Jo Van Damme{ddagger} and Alberto Mantovani*,{dagger}

* Istituto di Ricerche Farmacologiche "Mario Negri," Milan, Italy; {dagger} Department of Biotechnology, University of Brescia, Brescia, Italy; and {ddagger} Rega Institute for Medical Research, University of Leuven, Leuven, Belgium

IL-12 is a central cytokine in the activation of inflammation and immunity and in the generation of Th1-type responses. Tumor-associated macrophages (TAM) from mouse and human tumors showed defective production of IL-12. Defective IL-12 production was associated with lack of p50/p65 NF-{kappa}B activation. TAM produced increased amounts of the immunosuppressive cytokine IL-10. Abs against IL-10 restored the defective capacity of TAM to produce IL-12. Our data suggest that during tumor growth an IL-10-dependent pathway of diversion of macrophage function can be activated into the tumor microenvironment and results in the promotion of the IL-10+ IL-12- phenotype of TAM. Blocking IL-10, as well as other immunosuppressive cytokines present in the tumor microenvironment, such as TGF-{beta}, may complement therapeutic strategies aimed at activating type I antitumor immune responses.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.